A G. Haanen

Amsterdam, NH 1066CX, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Journal: Immuno-oncology technology

Published: August 04, 2025

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 10, 2025

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 28, 2025

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 23, 2025

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Journal: British journal of cancer

Published: January 13, 2025

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 23, 2024

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

Journal: ESMO open

Published: November 19, 2024

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 11, 2024

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 11, 2024

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 28, 2024

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

Journal: ESMO open

Published: February 10, 2024

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

Journal: ESMO open

Published: September 14, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026